The drug, Promacta, received the green light as a combination with standard immunosuppressive therapy to treat patients two years and older suffering from treatment-resistant severe aplastic anemia (SAA).
Novartis’ blood disorder drug gets FDA approval for expanded use
More from Industry NewsMore posts in Industry News »
- Frontline, medical workers need to take booster shots, say experts
- India tells Quad will allow export of 8 mln Indo-Pacific vaccine doses
- We need to be vigilant towards counterfeit products: Nakul Pasricha,President, ASPA
- India tops the chart for approved biosimilars and clinical trials surpassing USA and Europe: 10th Annual Pharma IPR India Conference